• NF 449 in P2X1 Platelet Studies

  2026-09-21

  NF 449 is a high-potency purinergic receptor antagonist for separating ATP-driven P2X1 signaling from broader platelet responses. This workflow-oriented guide covers receptor assays, collagen-induced platelet aggregation, thrombus models, and practical troubleshooting for antithrombotic agent research.

• Recombinant Mouse CD4, Tag Free Workflow

  2026-09-21

  Use Recombinant Mouse CD4, Tag Free as a defined reagent for binding, competition, and antibody-specificity assays that add immune context to placental necroptosis research. This workflow separates direct CD4 measurements from RIPK1–MLKL pathway readouts, helping researchers avoid overinterpreting a useful orthogonal assay as a disease surrogate.

• PD0325901: MEK Inhibition Meets Genome Folding

  2026-09-20

  A translational strategy for using PD0325901 to connect pathway engagement, cancer-cell phenotypes, xenograft evidence, and emerging principles of genome organization without overstating cross-domain biology.

• AY 9944 Dihydrochloride: DHCR7 Research Guide

  2026-09-19

  AY 9944 dihydrochloride is a selective DHCR7 inhibitor that drives 7-dehydrocholesterol accumulation by blocking its conversion to cholesterol. Product data report a 13 nM IC50 against recombinant human DHCR7, while 2026 genetic evidence links dhcr7 disruption to stronger antiviral resistance in grass carp.

• Q-VD-OPh: Reliable Caspase Inhibition

  2026-09-18

  Learn how Q-VD-OPh (SKU A1901) can clarify caspase-dependent cell death, support post-cryopreservation viability studies, and improve interpretation of apoptosis assays. This scenario-based guide covers experimental controls, solvent handling, data interpretation, and practical product selection.

• AY 9944 Dihydrochloride: Causal DHCR7 Assays

  2026-09-18

  AY 9944 dihydrochloride is a selective DHCR7 inhibitor for experimentally shifting sterol balance from cholesterol toward 7-dehydrocholesterol. This article develops a causal assay framework that connects biochemical inhibition with immune, membrane-raft, and emerging antiviral evidence while distinguishing chemical perturbation from permanent gene disruption.

• Dextromethorphan Hydrobromide for Neuroprotection

  2026-09-17

  Build more informative neuroprotection experiments with Dextromethorphan hydrobromide, an NMDA receptor antagonist tool that also affects voltage-operated ion currents. This guide connects concentration-response design, electrophysiology, excitotoxicity inhibition, and translational model selection while separating product facts from workflow starting points.

• Ciprofloxacin–RSL3 Ferroptosis via STING1–CAV2

  2026-09-17

  The reference study shows that ciprofloxacin can either suppress or enhance ferroptosis depending on the initiating stimulus: it potentiates RSL3-induced death by driving mitochondrial Zn2+ accumulation through a STING1–CAV2 pathway. Its findings connect topoisomerase 2β inhibition, mitochondrial DNA stress, zinc transport, and mitochondrial reactive oxygen species, while also defining practical considerations for cell viability measurement in ferroptosis experiments.

• Malate as a Flux and Redox Probe

  2026-09-16

  Malate and (S)-2-hydroxysuccinic acid provide a versatile way to interrogate TCA-cycle carbon flow, mitochondrial redox balance, and metabolic-immune signaling. This article translates recent cholangiocarcinoma findings into a practical assay framework that distinguishes flux effects from redox artifacts.

• TG003: From Splicing Control to CLK2 Translation

  2026-09-16

  TG003 is a research-grade Cdc2-like kinase inhibitor that connects reversible control of serine/arginine-rich protein phosphorylation with translational questions in alternative splicing, exon-skipping therapy, and CLK2-associated platinum resistance.

• AO/PI Cell Counting in Diabetic Nephropathy

  2026-09-15

  Learn how AO/PI Staining Solution and orthogonal viability measurements can strengthen mechanistic studies of diabetic nephropathy, including research on phillygenin, inflammation, and apoptosis.

• L. reuteri FN041 Reshapes Colitis-Associated Microbiota

  2026-09-15

  This mouse study shows that human milk-derived Limosilactobacillus reuteri FN041 alleviates DSS-induced colitis alongside improvements in intestinal barrier markers, inflammatory responses, gut microbiota, and cecal metabolites. Its multi-omics design supports a microbiota–metabolite mechanism, while the findings remain preclinical and require validation in controlled translational studies.

• NF 449: Designing Better P2X1 Platelet Assays

  2026-09-14

  NF 449 is a highly selective purinergic receptor antagonist for separating P2X1 signaling from broader platelet purinergic biology. This guide translates recombinant-receptor pharmacology into practical assay design, controls, storage decisions, and interpretation for platelet activation and thrombosis research.

• U0126 for MEK1/2 Mechanistic Assays

  2026-09-14

  U0126 converts substrate-stiffness experiments from pathway correlation into testable MEK1/2 causality. This practical guide connects PDMS mechanobiology, time-resolved ERK readouts, mineralization assays, and troubleshooting for reproducible MAPK/ERK pathway inhibition.

• Aβ42 Peptide: Ion Channels and Microglial Clearance

  2026-09-13

  A mechanistic guide to using human Amyloid β-Peptide (1-42) for integrated neurotoxicity, ion-channel, and microglial clearance studies in translational Alzheimer’s disease research.

510 records 1/34 page Next 12345 下5页 Last page